Uncommon Pulmonary Metastases and Metastasectomy: A Review
Kanthan R*†, Senger JL* and Kanthan SC‡

1Departments of Pathology and Laboratory Medicine, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
2Departments of Surgery, Royal University Hospital, University of Saskatchewan, Saskatoon, Saskatchewan, Canada

Abstract

Background: The development of pulmonary metastases is a critical step in oncology management as it is a major determinant of survival for patients with cancer. Primaries that commonly metastasize to the lung arise from breast, head/neck, and the gastrointestinal tract. The aim of this study was to review the pathobiogenesis of pulmonary metastases and the evolution of curative pulmonary metastasectomy as reported in the literature in addition to analyzing in detail uncommon pulmonary metastatic lesions received over a period of 14 years.

Design: The indexed uncommon pulmonary metastases were reviewed and analyzed in detail. A 14-year (1996-2010) computer-based review using the Laboratory-Information-System was conducted in our laboratory. Results were categorized based on age, sex, and primary sites of origin with special emphasis to study unusual pulmonary metastases.

Results: 230 cases of pulmonary metastases were retrieved on review. 129 females (56%) and 101 males (44%) ranging in age from 19 months to 91 years (median 65 years) were identified with their primary sites of origin being: breast (28.3%), gastrointestinal tract (27.8%), kidney (8.7%), and melanoma (7.0%). Three uncommon diagnoses were identified and studied in detail: 1) an index case of metastatic benign pleomorphic adenoma, case series of 2) endometrial stromal sarcoma and 3) osteosarcoma.

Conclusion: Due to the poor prognosis of metastatic lung cancer, early recognition with accurate diagnosis is an important step for optimal patient management. In this context, pathologic awareness of uncommon metastases remains a challenging task. Pulmonary metastasectomy is a curative option for an increasing number of patients due to recent advances in chemotherapy that achieve locoregional control of the primary tumours. With this increased number of pulmonary metastasectomy, recognition of not only ‘common’ pulmonary malignancies but also more rare entities becomes central to best practices in surgical pathology.

Background

Though the leading cause of cancer death among both sexes in Canada is lung cancer [1], the most common neoplasm in the lung is pulmonary metastases. Autopsy reports indicate 20-30% of all patients with neoplastic diseases of a malignant nature will demonstrate such lesions [2]. Pulmonary metastases occur when tumour cells detach from the primary and grow into the lungs by attaching to the basement membrane [3]. Once established in the parenchyma, local or extensive growth of the metastases results in the formation of a tumour [4]. Lung metastasis only develops from a small proportion of tumour cells arriving in the lungs by blood [5]. Most patients with metastasis to the lung are asymptomatic [4], and symptoms that do arise do not immediately appear; therefore upon clinical recognition, it is often too late for curative surgical resection [2]. Pulmonary metastasis is a diagnosis with poor prognosis, as it usually indicates extra-thoracic involvement of a primary tumour elsewhere. Ineffective systemic therapy also contributes to lowered survival rate. Such metastatic pulmonary lesions may be treated with chemotherapy, radiation therapy, immunotherapy, and surgery, with resection acting as the principle method of aggressive treatment with a curative goal [2].

First performed by Weinlechner [6] almost 125 years ago, pulmonary metastasectomy has been slow to gain acceptance [7]. Since 1882, imaging techniques for surveillance have improved dramatically, leading to earlier detection of these silent lesions and thus facilitating surgical treatment. With combination chemotherapy, pulmonary metastasectomy has become a part of a multi-factional treatment regime that offers the greatest hope for a cure [7]. As the literature validates the effectiveness of this treatment option, it is likely that as rates of pulmonary metastasectomies continue to rise there will be an increased number of surgical pathology lung specimens in the laboratory. In this context, awareness of the clinical and pathologic features of common and uncommon metastatic lesions is important to optimize future patient care.

The aim of this study was to review the pathobiogenesis of pulmonary metastases and the evolution of curative pulmonary metastasectomy as reported in the literature in addition to analyzing in detail uncommon pulmonary metastatic lesions received over a period of 14 years.

Methods

A comprehensive search of the Laboratory-Information-System (LIS) was used to identify patients with metastatic pulmonary lesions, with the exclusion of all hematopoietic malignancies. All surgical pathology reports were reviewed, analyzed, and categorized based on the histological-type and site of the primary neoplasm. These categories were then assessed and divided into common and
uncommon pulmonary lesions in congruent with the literature. The incidence of each type of lesion within both categories was calculated. The histopathological slides were retrieved and reviewed. Uncommon pulmonary metastases were analyzed carefully, and index cases of metastasizing benign pleomorphic adenoma, endometrial stromal sarcoma and osteosarcoma were studied in detail.

A literature search was conducted using the National Library of Medicine interface PubMed. The search terms “pleomorphic adenoma” or “metastasizing mixed” coupled with “lung” or “pulmonary” were selected. PubMed’s ‘Related Articles’ feature was used to extend our search. Articles obtained from their bibliographies and secondary references were identified and retrieved. The same process was carried out to identify literature regarding endometrial stromal sarcoma, using the key words “endometrial stromal sarcoma” and “lung metastases”. The evolution of the role of pulmonary metastasectomy as a method for curative treatment was reviewed with special focus on uncommon pulmonary lesions.

This study was conducted with ethics approval from the University of Saskatchewan Biomedical Research Ethics Review Committee.

Results

14-year surgical review

A review of fourteen years (1996-2010) revealed a total of 230 cases of pulmonary metastases; of these 177 (80%) were histopathology surgical specimens and 53 (20%) were fine needle aspiration cytology. Patient’s age ranged from 19 months to 92 years, averaging 61 years (median 65 years). 129 (56%) patients were female, and 101 (44%) were male. In our series, breast (65 cases, 28.3%) and gastrointestinal tract (64 cases, 27.8%) were the most common primaries, followed by the kidney (20 cases, 8.7%) and melanoma (16 cases, 7.0%). Other primary organ sites included thyroid (10 cases, 4.3%), uterus [7 cases total (3.0%)], testicle [5 cases total (2.2%)], bone (4 cases, 1.7%), prostate (4 cases, 1.7%), ovary (2 cases, 0.9%), squamous cell carcinoma (2 cases, 0.9%), Ewing’s sarcoma (2 cases, 0.9%) and pancreas (3 cases, 1.7%). 4 cases (1.7%) were determined to be undifferentiated high-grade malignancies originating from either the breast, colon, ovary, thyroid, kidney, or prostate. Uncommon primaries seen in our series included: neuroblastoma (1), malignant peripheral nerve sheath tumour (2), cholangiocarcinoma of the bile duct (1), squamous cell carcinoma of the cervix (1), chordoma (1) and metastasizing benign pleomorphic adenoma (1). The pathological material in all cases was reviewed. As the unusual metastases from chordoma and squamous cell carcinoma of the cervix have been previously reported from our laboratory [8,9] we elected to further elucidate the findings of metastatic benign pleomorphic adenoma (1), endometrial stromal sarcoma (4), and osteosarcoma (4).

Uncommon pulmonary metastases

Metastatic benign pleomorphic adenoma (1 case): A 58-year-old female with a nine-year history of chronic metastasizing benign pleomorphic adenoma, presented initially with a submandibular mass that reoccurred twice locally before metastasizing to the T-12 spine where it caused paraplegia. Repeated spinal recurrences were treated by surgical decompression. Postoperative CT scans of the thorax revealed a large amorphous soft tissue mass extending into the posterior mediastinum bilaterally with involvement of the lung parenchyma which was confirmed with a biopsy to be metastatic in origin. The patient died within a few months.

Histopathological analysis of the original submandibular specimen, spinal lesion and the lung mass showed identical features of a biphasic tumour composed of the epithelial component with ductal structures admixed with the mesenchymal-like component of mucoid/myxoid/cartilaginous stroma (Figure 1a, b, c). There was no evidence of increased mitotic activity or progressive cellular or nuclear atypia in the lung sections (Figure 1d).

Endometrial Stromal Sarcoma (4 cases): Four cases of endometrial stromal sarcoma (ESS) were identified in our review. Patients were aged 49, 50, 66 and 69 and were equally distributed in the right and left lungs. In two cases the lung lesion was composed of well-circumscribed, capsulated nodules (Figure 2a) and the other two were ill-defined non-encapsulated masses (Figure 2b).

Histopathological analysis of all cases revealed identical findings of the presence of a spindle cell lesion arranged in ill-defined whorls, composed of fairly uniform cells with mild nuclear atypia and a growth pattern highly reminiscent of endometrial stromal cells (Figure 2c, 2d). Immunohistochemically these neoplastic cells showed strong staining to estrogen and progesterone receptor antibodies with diffuse cytoplasmic staining for CD10 and vimentin. In three of the four cases the lung lesions closely resembled the original primary uterine lesion.

Osteosarcoma (4 cases): Four cases of osteosarcoma were identified, three of which were paediatric in origin. Patients were aged 10 (F), 10 (F), 16 (M), and 42 (M) years. Specimens received in the laboratory included wedge resection of the left lung (1), multiple nodules in the right lung (1), and partial resection of right and left lobes of the lungs (2).

Histopathological examination of all cases confirmed the presence of malignant cells forming osteoid establishing the diagnosis of osteogenic sarcoma (Figure 3a). The matrix varied between osteoblastic in one case as seen in Figure 3b and chondroblastic in another as seen in Figure 3c. The lesional cells were a heterogeneous mixture of spindle,
have been identified that may contribute to the heightened incidence of a non-pulmonary primary [11]. Five features of the pulmonary system disease [10], and secondary tumours occur in 20-50\% of patients with... increased abnormal mitosis and necrosis (Figure 3d).

Discussion

The lungs are the organ most frequently affected by metastatic disease [10], and secondary tumours occur in 20-50\% of patients with a non-pulmonary primary [11]. Five features of the pulmonary system have been identified that may contribute to the heightened incidence of such metastases. These include: a) it continually retrieves the entire right-sided cardiac output, b) it contains a high-density capillary bed, c) it is the first capillary plexus met by cells after lymphatic drainage enters the venous system, and d) it consist of delicate membranes that may draw on oxygenated air to promote sustenance [12,13]. The high levels of vascularization and richness of oxygen in the lungs provides an environment rich in the nutrients required for neoplastic growth [14]. Autopsy series demonstrate that 20-54\% of patients who died from malignant disease had pulmonary metastases; however, the reported clinical consequence and the impact on quality of life remain variable [15]. Most patients with pulmonary metastases are asymptomatic, with only 5-15\% developing symptoms over time such as dyspnoea, cough, hemoptysis, chest pain, or a pneumothorax [11]. Hemoptysis suggests endobronchial metastases, while dyspnoea is believed to be related to the tumour replacing the parenchyma, and pain may signify involvement of the parietal pleura [11]. Additionally, pneumothoraces present in up to 10\% of patients, particularly those with a sarcomatous primary [11].

Common extrathoracic primary origins include the kidney (92\%), skin (78\%), breast (72\%), thyroid (57\%), pancreas (56\%), prostate (50\%), stomach (47\%), uterus (44\%), colon (41\%) [16]; however, virtually any primary malignancy can metastasize to the lung [12]. In our surgical pathology review over the past 14 years, the common sites of the primary lesion included the breast (28.3\%), gastrointestinal system (27.8\%), kidney (8.7\%), skin (7.0\%), and thyroid (4.3\%). These incidences are less frequent than those reported in the literature. Our series did not confirm any lesions consistent with origin from the stomach. Such discrepancies may be related to a small sample size.

Adenocarcinomas have a greater propensity for this pattern of dispersion than other extra-thoracic solid tumours, as seen in our surgical review [12]. Metastases to the lung may take many forms: solitary and multiple parenchymal nodules, lymphangitic carcinomatosis [17], tumour emboli, endobronchial metastases, and pleural effusions [18]. Dissemination of these primaries chiefly occurs via haematogenous spread [10]. Malignant cells may enter the venous blood either directly or through the lymph drainage, and this pathway is generally attributed to metastases from the head/neck, thyroid, adrenal, kidney, testes, melanoma, or osteosarcoma [13]. Less common forms of dissemination include seeding through the metastatic involvement of other organs and direct extension of the cancer through lymphatics that traverse those structures [13,17].

Metastatic lung cancer is associated with a poor prognosis, and best-practice management involves a multidisciplinary approach with the oncologist, a thoracic surgeon, and a subspecialty radiologist. Typical features of lung metastases depend heavily on the origin and type of primary, and often includes cavitation, calcification, and either a diffuse miliary seeding or a large single metastasis [10]. These lesions are commonly detected on chest x-ray (CXR) as solitary or multiple well-circumscribed, pulmonary nodules with a broad range of size and shape [15]. Differential benign diagnoses include granulomas, sterilised metastases, infection, and proliferation of intrapulmonary nodes [10,13]. Modern imaging equipment has enhanced our ability to understand what is occurring within an internal organ, and as such it should come as no surprise that thin collimated helical scans are able to detect 20-25\% more pulmonary lesions than the ordinary CT scan [7]. In addition, a PET scan with F-labeled fluoro-2-deoxy-D-glucose is able to detect neoplastic disease with a pulmonary sensitivity of more than 90\% for nodules greater than 7 mm [7]. Increasing specificity and sensitivity in these methods of detection may provide an early...
Table 1: A 14 Year Surgical Pathology Review of Pulmonary Metastases (Saskatoon Lab Information System 1997-2010).

<table>
<thead>
<tr>
<th>Histological Diagnosis</th>
<th>Site of Primary</th>
<th>Frequency</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenocarcinoma</td>
<td>Breast</td>
<td>65</td>
<td>28.3%</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>Gastrointestinal (colorectal)</td>
<td>64</td>
<td>27.8%</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>Prostate</td>
<td>4</td>
<td>1.7%</td>
</tr>
<tr>
<td>Adenocarcinoma</td>
<td>Pancreas</td>
<td>3</td>
<td>1.3%</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>Bile ducts</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Serous adenocarcinoma</td>
<td>Ovary</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Urothelial carcinoma</td>
<td>Kidney</td>
<td>20</td>
<td>8.7%</td>
</tr>
<tr>
<td>Papillary carcinoma</td>
<td>Thyroid</td>
<td>10</td>
<td>4.3%</td>
</tr>
<tr>
<td>Melanoma</td>
<td>Skin</td>
<td>16</td>
<td>7.0%</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>Skin</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>Base of tongue</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>Cervix</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Squamous cell carcinoma</td>
<td>Esophagus</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Endometrioid carcinoma</td>
<td>Endometrium</td>
<td>3</td>
<td>1.3%</td>
</tr>
<tr>
<td>Endometrial stromal sarcoma</td>
<td>Endometrium</td>
<td>4</td>
<td>1.7%</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>Uterus</td>
<td>3</td>
<td>1.3%</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>Inferior vena cava</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Leiomyosarcoma</td>
<td>Left leg</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Seminoma</td>
<td>Testicle</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Embryonal Carcinoma</td>
<td>Testicle</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Rhabdomyosarcoma</td>
<td>Testicle</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Adenoid Cystic Carcinoma</td>
<td>Salivary gland-parotid</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Metastasizing pleomorphic adenoma</td>
<td>Salivary gland-submandibular</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Osteosarcoma</td>
<td>Femur</td>
<td>4</td>
<td>1.7%</td>
</tr>
<tr>
<td>Chondrosarcoma</td>
<td>Right Femur</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Ewing's sarcoma</td>
<td>Chest wall mass</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Hepatocellular carcinoma</td>
<td>Liver</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Neuroblastoma</td>
<td>Adrenal</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Malignant peripheral nerve sheath tumour</td>
<td>Right neck</td>
<td>2</td>
<td>0.9%</td>
</tr>
<tr>
<td>Malignant Mesothelioma</td>
<td>Mesothelium</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Liposarcoma</td>
<td>Thigh</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Chordoma</td>
<td>Spine</td>
<td>1</td>
<td>0.4%</td>
</tr>
<tr>
<td>Undifferentiated high-grade malignancy- poorly differentiated adenocarcinoma</td>
<td>Breast, colon, ovary, thyroid, kidney, prostate or GI</td>
<td>4</td>
<td>1.7%</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td><strong>230</strong></td>
<td><strong>100%</strong></td>
</tr>
</tbody>
</table>

The presence of a single pulmonary nodule presents diagnostic difficulty, as incidence of solitary primary lung lesions is more common than solitary metastatic lung lesions [10]. One-fifth of all pulmonary metastases will present as solitary nodules with no evidence of involvement of either the lymphatics or extra-pulmonary organs [11]. Metastatic lesions are generally a) smaller than primaries b) grow more rapidly, c) located more in the lower lobes and outer parts of the lungs and d) have more well-circumscribed margins than primary malignant tumours [16]. Over 80% of metastatic lesions are less than 1 cm, which is the lower limit of CXR detection [11]. As earlier detection of pulmonary metastases continues to increase due to technological advancements and pulmonary metastasectomy gains acceptance, the number of lung specimens arriving in the surgical laboratory is correspondingly increasing. When metastatic disease is suspected in a pulmonary lesion, comparison with the primary lesion supplemented by ancillary techniques such as immunohistochemical studies may help in confirming the exact diagnosis. Such accurate pathological diagnosis is clinically essential to guide treatment protocols.

Four possible treatment plans for pulmonary metastases include chemotherapy, immunotherapy, radiotherapy, and surgical resection. Chemotherapy, though rarely curative, may postoperatively aid in the
control of systemic micro-metastases. When combined with resection, it improves the prognosis for patients with sarcomas, testicular, colorectal, and renal carcinoma. In addition, its neo-adjuvant use may reduce tumour burden improving surgical resectability [7].

Immunotherapy is the selected treatment for certain metastatic lesions that express immunogenic antigens as in melanoma, in which it may serve as front-line therapy [2]. Radiotherapy is not normally associated with an increase in survival as the required dose for tumour control is greater than the tolerance level of the pulmonary tissue; therefore, this treatment is purely palliative [2]. Though their success rates do not yet match those of surgical intervention, stereotactic body radiation therapy and radiofrequency ablation are options for patients at a high surgical risk with reported 1-year survival rates of 85% [14].

The first surgical removal of a pulmonary metastasis was carried out in 1822 by Weinlechner [6] and since then the goal of this procedure has been to eradicate tumour with preservation of the lung parenchyma to the greatest possible extent. A complete resection requires all surgical margins to be microscopically negative, and is a strong predictor of improved survival [7]. It was initially believed that pulmonary metastases were indicative of systemic dissemination, with surgical resection providing no survival benefit. It is now believed that under the proper conditions, complete pulmonary metastasectomy offers a potentially curative treatment [2,19]. An expansion of Alexander and Haight’s [20] criteria that must be fulfilled for a patient to be eligible for curative pulmonary metastasectomy are: a) no disease present at the primary tumour site, b) no metastases present outside the lungs, c) no non-resectable pulmonary nodules present, d) no nonsurgical alternative for cure, and e) the patient should be able to tolerate the surgical treatment [15]. Achieving the first criteria is highly dependent on the histological nature of the primary, as sarcomas, renal cell cancers and head and neck cancers will often spread preferentially to the lungs whereas melanoma, breast and colon cancers are more widely disseminated [14]. Pulmonary metastasectomy may be carried out beginning four weeks after complete resection of the primary lesion, and patients with bilateral metastases should first undergo resection of the least-involved lung to determine the resectability of the lesion [2]. ‘Resectability’ encompasses the location, status, and number of lesions, as well as individual patient factors [7]. Most pulmonary metastases are either locally unresectable or synchronous with other metastases with only 1% of pulmonary tumours being resectable [4]. Survival is optimized by this treatment when tumours are solitary and less than 3cm in diameter [15]. 3-year success rates as high as 78%, and 10-year survival rates of 26% have been reported [14]. Patients with a sarcomatous primary lesion generally benefit the most from pulmonary metastasectomy due to the tumour’s high propensity for exclusive pulmonary spread [7].

Video-assisted thoracoscopic surgery (VATS) remains a controversial approach to the treatment of pulmonary metastases. This newest approach confers excellent surgical access, reduced hospital stay, minimal postoperative pain, and improved long-term quality of life. These results may be attributed to a reduced incision length (5-8 cm) compared with that of tumour resection (30-40cm) which correlates with a reduction of systemic stress [7]. The downside includes the possibility of small nodules going undetected as the procedure does not allow lung palpation, and consequently tumours may recur along the thoracoscopic surgical tracts [14,15]. Open thoracotomy has been shown to be more capable of detecting pulmonary lesions when compared to VATS [5].

Prognostic indicators including site and type of primary, length of disease-free interval, number of metastases identified, and doubling time of the tumour are criteria used to select patients for metastasectomy [24]. To be considered, the primary tumour must be under control with no evidence of widespread extra-pulmonary metastases, and the patients must be expected to have sufficient pulmonary function postoperatively [4]. When metastases involve the pleura, chest wall, or other intra-thoracic structures, en-bloc resection or pneumonectomy may be required [4]. Completeness of resection is the primary factor in determining the rate of local recurrence and long-term survival [5]. Up to 30% of patients with pulmonary metastases are reported with positive mediastinal lymph nodes, a finding that lowers the 3-year survival rates by 30% [5].

We will now discuss the index cases selected for detail review in this study.

**Metastatic benign pleomorphic adenoma (1 case):** Mixed tumours, or pleomorphic adenoma (PA) is the commonest benign neoplasm, representing 3.6% of all salivary gland tumours. Malignancy of PA can be classified into three categories: a) carcinoma ex pleomorphic adenoma (CXA): carcinoma arising in the background of PA b) carcinosarcoma: biphasic malignant tumour of the epithelial and mesenchymal components and c) metastasizing malignant pleomorphic adenoma (MPA) [21]. Also known as metastasizing benign pleomorphic adenoma, the paradoxical nature of MPA poses the evident question of how a benign lesion can metastasize. The neoplasm is composed of two components: benign ductal structures and myoepithelial cells from an epithelial element and a metaplastic mesenchymal element with fibrous/chondroid/myxoid features [22]. Such distant metastases are often histologically identical to the primary PA [23,24]. Prior to metastases, 90% of MPA will have reoccurred several times at the primary site, with the reported length of time interval between the occurrence of the primary and the metastatic lesions averaging 16 years [21,25,26]. MPA has been associated with metastases to the bone, lung, lymph nodes, kidney, liver, central nervous system, retroperitoneum, and skin, and spreads haematogenously rather than lymphatically [25]. Reports indicate a relationship between incomplete surgical excision of the primary tumour and the incidence of distant ‘metastases’. Further, as chemotherapy and radiotherapy are generally ineffective in combating this disease, surgery is the treatment of choice, and is associated with a survival advantage [25-27]. A relevant clinical history is essential for the accurate pathological diagnosis of such rare pulmonary lesions [25].

**Endometrial stromal sarcoma (4 cases):** Endometrial stromal sarcoma (ESS) is a rare tumour representing 20% of uterine sarcomas [28] and only 0.2% of uterine malignancies [29,30]. Depending on the highest mitotic count, ESS is divided into two categories: low-grade (<10 mitoses/high power field) accounting for 2/3 of ESS diagnosis or high-grade (>10 mitoses/high power field) comprising the other 1/3 [29,31]. Low-grade ESS is more common and slow-growing with a 5-year survival of 80-100% whereas the high-grade has a more aggressive course with a 37-60% recurrence rate [32]. On average, women are 40-45 years old, and most present at clinical stage I [31]. ESS recurrence develops in a third to half of patients, and the time interval after the initial treatment may be as long as 30 years [29]. Recurrence is often limited to the pelvis, and abdomen [31]. The incidence of extra-pelvic spread with pulmonary metastases varies from 7-28%, commonly presenting as multiple pulmonary nodules [33]. Metastatic pulmonary ESS may be an incidental finding in an asymptomatic person, or a
metastases such as those from metastasizing benign pleomorphic adenoma, endometrial stromal sarcoma and osteosarcoma though a challenging task is essential for appropriate patient management.

References


